Cefadroxil

AND CLINICAL USE APO-CEFADROXIL (cefadroxil) is indicated for the treatment of the following infections when caused by susceptible strains of the organisms indicated: – Acute uncomplicated urinary tract infections when caused by E.

coli, Klebsiella species and some strains of Proteus mirabilis. – Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß -hemolytic streptococci. – Acute pharyngitis-tonsillitis, when caused by Group A ß -hemolytic streptococci.

– Lower respiratory tract infections, including pneumonia, caused by S. pneumoniae (D. pneumonia), S. Pyogenes (Group A ß -hemolytic streptococci), K. pneumoniae and S. aureus. Prior to and during therapy, appropriate bacteriological studies should be performed in order to identify and determine the susceptibility of the causative organism(s).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO- CEFADROXIL and other antibacterial drugs, APO-CEFADROXIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species.

Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci).

Note:

Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available.

Note:

Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Cefadroxil is a cephalosporin antibiotic bactericidal in vitro against a wide range of Gram-positive and Gram-negative microorganisms. Cefadroxil is indicated in the treatment of the following infections when due to susceptible microorganisms.

Respiratory tract infections:

Tonsillitis, pharyngitis, lobar and bronchopneumonia, acute and chronic bronchitis, pulmonary abscess, empyema, pleurisy, sinusitis, laryngitis, otitis media.

Skin and soft-tissue infections:

Lymphadenitis, abscesses, cellulitis, decubitus ulcers, mastitis, furunculosis, erysipelas.

Genitourinary tract infections:

Pyelonephritis, cystitis, urethritis, gynaecological infections.

Other infections: